Bladder cancer (BC) is the second most frequent genitourinary cancer, with an increasing global survivor population. Over the last two decades, there has been a growing understanding of not only the oncology but also the quality of life implications of a BC diagnosis, therapy, and monitoring. For a review, researchers summarized and analyzed the literature on the many aspects of bladder cancer survival. Efforts to reduce perioperative morbidity, particularly in patients undergoing radical cystectomy, yielded mixed results. With validated measures specific to BC patients, there was a growing emphasis on the short and long-term health-related quality of life (HR-QoL) impacts of bladder cancer, spanning the domains of physical and mental QoL related to urinary function, sexual function, and financial and psychological burden. There were still differences in oncologic outcomes based on race and gender. BC had a long-term impact, and there was an unmet demand for long-term support and survivorship tools to address this.

The global number of bladder cancer patients was rising, and their demands were complicated, varying by stage, therapy, and certain demographic factors. Outcome-centered perioperative techniques had the potential to reduce treatment morbidity and validated BC-specific HR-QoL instruments helped to identify the effect and burden of BC, but there were still significant areas of unmet need that required more research and intervention.